Learn More
R&D Systems™ Recombinant Human B7-H3 Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 1027B3100
Description
Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED50 for this effect is 3-12 μg/mL. Optimal dilutions should be determined by each laboratory for each application.Specifications
NP_079516 | |
Lyophilized from a 0.2 µm filtered solution in PBS. | |
M.W. (Observed): 70-80 kDa, reducing conditions; M.W. (theoretical): 50 kDa (monomer) | |
100 µg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution. | |
<0.10 EU / 1 µg of the protein by the LAL method. | |
Unconjugated | |
Reconstitute at 100 µg/mL in sterile PBS. | |
B7-H3/CD276 |
Bioactivity | |
80381 | |
B7-H3 Fc Chimera | |
Mouse myeloma cell line, NS0-derived human B7-H3 protein Human B7-H3 (Leu29-Pro245) (N-terminus) Accession # NP_079516 DIEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) | |
Disulfide-linked homodimer | |
CD276 | |
Recombinant | |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining. |
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.